Current Gastroenterology Reports

, Volume 8, Issue 6, pp 470–477

Advances in the pathogenesis of inflammatory bowel disease

Article

Abstract

Most people do not develop inflammatory bowel disease (IBD) in spite of the density of the commensal flora. In the past few years, several areas of gut mucosal immunology have emerged that will permit advances in the management of IBD at the bedside. The commensal flora is only beginning to be fully appreciated as another metabolic organ in the body. Innate immunity as it relates to the gut has complemented our understanding of the adaptive immune response. The most important susceptibility gene described for Crohn’s disease, the NOD2 gene, participates in the innate immune response to pathogens. Patients carrying NOD2 mutations have an increased adaptive immune response to commensal organisms as measured by higher titers of antimicrobial antibodies, such as anti-CBir and anti-Saccharomyces cerevisiae antibodies. Toll-like receptors expressed by antigen-presenting cells (APCs) in the gut and intestinal epithelial cells also play a role in recognition of intestinal flora. Within the APC category, dendritic cells link the innate and adaptive immune systems and shape the nature of the adaptive immune response to commensal bacteria. With respect to adaptive immunity, a new signaling pathway involving a distinct helper CD4 T-cell subset producing interleukin-17 may become a target for the treatment of chronic inflammatory diseases. This review focuses on developments likely to culminate in advances in patient care.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Garcia Rodriguez LA, Ruigomez A, Panes J: Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006, 130:1588–1594.CrossRefGoogle Scholar
  2. 2.
    Sonnenburg JL, Xu J, Leip DD, et al.: Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 2005, 307:1955–1959. Germ-free mice were fed Bacteroides thetaiotaomicron. Depending on the available food source, B. thetaiotaomicron displayed flexible foraging behavior that contributed to ecosystem stability and functional diversity.PubMedCrossRefGoogle Scholar
  3. 3.
    Gill SR, Pop M, Deboy RT, et al.: Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355–1359. This study supports the notion that humans are "superorganisms" whose metabolism integrates microbial and human features.PubMedCrossRefGoogle Scholar
  4. 4.
    Swidsinski A, Loening-Baucke V, Lochs H, Hale LP: Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005, 11:1131–1140.PubMedGoogle Scholar
  5. 5.
    Eckburg PB, Bik EM, Bernstein CN, et al.: Diversity of the human intestinal microbial flora. Science 2005, 308:1635–1638.PubMedCrossRefGoogle Scholar
  6. 6.
    Manichanh C, Rigottier-Gois L, Bonnaud E, et al.: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006, 55:205–211.PubMedCrossRefGoogle Scholar
  7. 7.
    Sokol H, Seksik P, Rigottier-Gois L, et al.: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:106–111.PubMedCrossRefGoogle Scholar
  8. 8.
    Sartor RB: Does Mycobacterium avium subspecies paratuberculosis cause Crohn’s disease? Gut 2005, 54:896–898. A concise update appraises the evidence for and against MAP as an etiopathogenetic factor for CD.PubMedCrossRefGoogle Scholar
  9. 9.
    Autschbach F, Eisold S, Hinz U, et al.: High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn’s disease. Gut 2005, 54:944–949.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakase H, Nishio A, Tamaki H, et al.: Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn’s disease. Inflamm Bowel Dis 2006, 12:62–69.PubMedCrossRefGoogle Scholar
  11. 11.
    Polymeros D, Bogdanos DP, Day R, et al.: Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn’s disease? Gastroenterology 2006, 131:85–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Peltekova VD, Wintle RF, Rubin LA, et al.: Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004, 36:471–475.PubMedCrossRefGoogle Scholar
  13. 13.
    Fries W, Renda MC, Lo Presti MA, et al.: Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn’s disease in Southern Italy. Am J Gastroenterol 2005, 100:2730–2736.PubMedCrossRefGoogle Scholar
  14. 14.
    Ouellette AJ, Bevins CL: Paneth cell defensins and innate immunity of the small bowel. Inflamm Bowel Dis 2001, 7:43–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Wehkamp J, Salzman NH, Porter E, et al.: Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci U S A 2005, 102:18129–18134.PubMedCrossRefGoogle Scholar
  16. 16.
    Wehkamp J, Harder J, Weichenthal M, et al.: NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658–1664.PubMedCrossRefGoogle Scholar
  17. 17.
    Kobayashi KS, Chamaillard M, Ogura Y, et al.: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731–734. The role of NOD2 was studied in NOD2 -/- mice, which showed increased susceptibility to Listeria monocytogenes infection mediated through Paneth cells.PubMedCrossRefGoogle Scholar
  18. 18.
    Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000, 68:7010–7017.PubMedCrossRefGoogle Scholar
  19. 19.
    Torok HP, Glas J, Tonenchi L, et al.: Crohn’s disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004, 127:365–366.PubMedCrossRefGoogle Scholar
  20. 20.
    Franchimont D, Vermeire S, El Housni H, et al.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 2004, 53:987–992.PubMedCrossRefGoogle Scholar
  21. 21.
    Arnott ID, Nimmo ER, Drummond HE, et al.: NOD2/ CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn’s disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004, 5:417–425.PubMedCrossRefGoogle Scholar
  22. 22.
    Fukata M, Michelsen KS, Eri R, et al.: Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1055-G1065.PubMedCrossRefGoogle Scholar
  23. 23.
    Fukata M, Chen A, Klepper A, et al.: Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling and is important for proliferation and apoptosis in response to intestinal mucosal injury. Gastroenterology 2006, 131:862–877.PubMedCrossRefGoogle Scholar
  24. 24.
    Hugot JP, Chamaillard M, Zouali H, et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001, 411:599–603.PubMedCrossRefGoogle Scholar
  25. 25.
    Ogura Y, Bonen DK, Inohara N, et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 411:603–606.PubMedCrossRefGoogle Scholar
  26. 26.
    Maeda S, Hsu LC, Liu H, et al.: Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005, 307:734–738. This study complements that of Kobayashi et al. [17].PubMedCrossRefGoogle Scholar
  27. 27.
    Rescigno M: CCR6(+) dendritic cells: the gut tacticalresponse unit. Immunity 2006, 24:508–510.PubMedCrossRefGoogle Scholar
  28. 28.
    Niess JH, Brand S, Gu X, et al.: CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005, 307:254–258. Lamina propria dendritic cells depend on the chemokine receptor CX3CR1 to form transepithelial dendrites. These projections control host interactions with commensal and pathogenic bacteria.PubMedCrossRefGoogle Scholar
  29. 29.
    Imai T, Hieshima K, Haskell C, et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521–530.PubMedCrossRefGoogle Scholar
  30. 30.
    Pan Y, Lloyd C, Zhou H, et al.: Neurotactin, a membraneanchored chemokine upregulated in brain inflammation. Nature 1997, 387:611–617.PubMedCrossRefGoogle Scholar
  31. 31.
    Jung S, Aliberti J, Graemmel P, et al.: Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000, 20:4106–4114.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhao X, Sato A, Dela Cruz CS, et al.: CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer’s patch CD11b+ dendritic cells. J Immunol 2003, 171:2797–2803.PubMedGoogle Scholar
  33. 33.
    Salazar-Gonzalez RM, Niess JH, Zammit DJ, et al.: CCR6-mediated dendritic cell activation of pathogenspecific T cells in Peyer’s patches. Immunity 2006, 24:623–632.PubMedCrossRefGoogle Scholar
  34. 34.
    Fuss IJ, Becker C, Yang Z, et al.: Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are downregulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12:9–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Mannon PJ, Fuss IJ, Mayer L, et al.: Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004, 351:2069–2079.PubMedCrossRefGoogle Scholar
  36. 36.
    Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5:521–531. This article reviews recent studies supporting a central role for IL-23 in stimulating a subset of Th cells to become IL-17-producing Th cells.PubMedCrossRefGoogle Scholar
  37. 37.
    Bettelli E, Sullivan B, Szabo SJ, et al.: Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 2004, 200:79–87.PubMedCrossRefGoogle Scholar
  38. 38.
    McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL- 23-IL-17 immune pathway. Trends Immunol 2006, 27:17–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Heller F, Fuss IJ, Nieuwenhuis EE, et al.: Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629–638.PubMedCrossRefGoogle Scholar
  40. 40.
    Fuss IJ, Heller F, Boirivant M, et al.: Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004, 113:1490–1497.PubMedCrossRefGoogle Scholar
  41. 41.
    Infante-Duarte C, Horton HF, Byrne MC, Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107–6115.PubMedGoogle Scholar
  42. 42.
    Yen D, Cheung J, Scheerens H, et al.: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310–1316. With the use of IL-23p19 null and IL-12p35 null mice, the investigators demonstrate that IL-23 but not IL-12 is essential for the development of intestinal inflammation.PubMedCrossRefGoogle Scholar
  43. 43.
    Summers RW, Elliott DE, Urban JFJr, et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825–832.PubMedCrossRefGoogle Scholar
  44. 44.
    Metwali A, Setiawan T, Blum AM, et al.: Induction of CD8+ regulatory T cells in the intestine by Heligmosomoides polygyrus infection. Am J Physiol Gastrointest Liver Physiol 2006, 29:G253-G259.CrossRefGoogle Scholar
  45. 45.
    Brimnes J, Allez M, Dotan I, et al.: Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005, 174:5814–5822.PubMedGoogle Scholar
  46. 46.
    Kraus TA, Toy L, Chan L, et al.: Failure to induce oral tolerance in Crohn’s and ulcerative colitis patients: possible genetic risk. Ann N Y Acad Sci 2004, 1029:225–238.PubMedCrossRefGoogle Scholar
  47. 47.
    Kraus TA, Toy L, Chan L, et al.: Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 2004, 126:1771–1778. This is the first study to test whether development of oral tolerance is impaired in patients with IBD. One group of investigators has explored the use of colon protein antigens in patients with CD to induce oral tolerance. The findings of this paper make it unlikely that oral tolerance strategies would be effective in IBD.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Inflammatory Bowel Disease CenterMount Sinai School of MedicineNew YorkUSA

Personalised recommendations